Laxico

Short-term relief of acute mild to moderate pain. Symptomatic relief of pain & inflammation in OA & RA.

Individualized dosage. Moderate or significant pain syndrome 8-16 mg daily in 2-3 divided doses. Inflammatory & degenerative rheumatic disease Initially 12 mg in 2-3 divided doses. Max: 16 mg daily. Patient w/ moderate to severe renal failure, severe hepatic insufficiency 12 mg daily in 2-3 divided doses.

Should be taken on an empty stomach.

Hypersensitivity to lornoxicam or other NSAIDs including ASA. Thrombocytopenia; severe heart failure; GI, cerebrovascular or other bleeding disorders; history of GI bleeding or perforation related to previous NSAIDs therapy; active or history of recurrent peptic ulcer/hemorrhage (≥2 distinct episodes of proven ulceration or bleeding). Severe hepatic & renal (serum creatinine >700 micromol/L) impairment. Pregnancy & lactation. Childn <18 yr.

Discontinue use at 1st appearance of symptoms of serious skin adverse reactions eg, skin rashes, mucous membrane lesions & other sign of hypersensitivity; if renal function deteriorates; if any adverse reactions occur on digestive tract; if increases in transaminases, serum bilirubin, & conc of urea & creatinine in blood are significant or persist. Avoid use in case of varicella. Patients w/ HTN &/or heart failure; uncontrolled arterial HTN, CHF, CHD, cerebrovascular disorders, elevated risk factors for CV disease eg, HTN, hyperlipidemia, diabetes, smoking; suffering from or w/ previous history of bronchial asthma; who are prone to bleeding. Monitor renal functions in patients who undergo major surgery, w/ cardiac failure, receiving diuretics & drugs suspected to or known to be able to cause kidney damage. Careful clinical monitoring & regular lab assessments are recommended in patients w/ blood coagulation disorders &/or hepatic impairment. Regular lab assessments of Hb, creatinine & liver enzymes are recommended in long-term treatment (>3 mth). Concomitant use w/ drugs increasing risk of ulcers & bleeding; heparin; tacrolimus. Avoid concomitant use w/ NSAIDs including COX-2 selective inhibitors. Not to be used by patients w/ galactose intolerance, lactase deficiency, or impaired glucose-galactose absorption. Patients experiencing dizziness or other central nervous disturbances should refrain from driving or operating machinery. Patients w/ mild (serum creatinine 150-300 micromol/L) to moderate (serum creatinine 300-700 micromol/L) renal impairment. Can weaken fertility; not recommended in women attempting to conceive. Monitor renal & hepatic function in elderly >65 yr. Post-op elderly patients.

Mild short-term headache, dizziness, nausea, abdominal pain, indigestion, diarrhea, vomiting.

Increased plasma conc w/ cimetidine. May enhance effects of anticoagulants eg, warfarin. Decreased effect of phenprocoumon. Increased risk of spinal or epidural haematoma w/ heparin in context of spinal or epidural anaesth. May decrease antihypertensive effect of ACE inhibitor. Decreased diuretic & antihypertensive effect of loop, thiazide & K-sparing diuretics. Decreased antihypertensive efficacy of β-adrenergic blockers or ARB. Decreased renal clearance of digoxin. Increased risk of GI ulceration or bleeding w/ corticosteroids. Increased risk of seizures w/ quinolones. Increased risk of GI bleeding w/ antiplatelets; other NSAIDs; SSRIs. Increased serum conc of MTX which may result to increased toxicity. May increase serum conc of lithium above toxicity limits. Increased serum conc of cyclosporine. May enhance nephrotoxicity of cyclosporine via renal prostaglandin-mediated effects. Increased risk of hypoglycaemia w/ sulphonylureas eg, glibenclamide. Interaction w/ known CYP2C9 inducers & inhibitors. Increased risk of nephrotoxicity w/ tacrolimus. May reduce renal clearance of pemetrexed resulting in increased renal & GI toxicity, & myelosuppression.

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

M01AC05 - lornoxicam ; Belongs to the class of non-steroidal antiinflammatory and antirheumatic products, oxicams.

Rx